Clinical Efficacy And Serum Hypersensitive C-reactive Protein,interleukin-6 And S100B Protein In Patients With Acute Ischemic Stroke Treated By Intravenous Injection Of Edaravone Dextropenol After Intravenous Thrombolysis With Ateplase

ObjectiveTo observe the effect of intravenous injection of Edaravone dextromethrin on neurological function score and serum levels of hs-CRP,IL-6 and S100B in patients with ACI after intravenous thrombolysis with alteplase.To explore the effect of RIC on the recovery of neurological function in patients with ACI and its possible brain protective mechanism.MethodsFrom December 2021 to December 2022,90 individuals suffering from acute ischemic stroke,treated with rt-PA through intravenous thrombolysis,were selected as participants at Shenyang Medical College’ s Department of Neurology Employing random number tables,4 5 experimental and 4 5 control groups were divided.Following thrombolysis with alteplase,the experimental group underwent routine treatment with Edaravone and Dexborneol.This was achieved by administering 15 ml of Edaravone rightcamphor,followed by 100ml of 0.9%sodium chloride intravenously twice daily for 10 days.For 10 days,the control group’s patients underwent a standard regimen of treatment.The routine treatment of the two groups was based on the Chinese guidelines for diagnosis and treatment of Acute Ischemic Stroke 2021 to improve microcirculation,statins,antiplatelet therapy,and to control blood pressure,blood lipids and blood sugar at normal levels.On the initial day of treatment,alterations in clinical effectiveness,the NIHSS,modified RANKIN scale,and Barthel Indexwere noted,followed by 10 days post-treatment and 90±7 days of long-term prognosis.The 1st and 10±2th days post-admission saw alterations in serum hypersensitive C-reactive protein(hs-CRP),interleukin-6(IL-6)and S100B protein levels,as well as adverse reactions during the course of treatment.The efficacy and brain protection of Edaravone and Dexborneol,administered intravenously after thrombolysis with alteplase,in treating acute ischemic stroke,can be observed.Results1.Comparison of general baseline data between the two groupsA total of 90 subjects were included in this study,all of them completed the whole experimental process,No shedding cases were present.Randomly,4 5 patients were split into two groups,with 21 males and 24 females in the control group and 25 males and 20 females in the experimental group.No noteworthy disparity existed between the two groups in terms of age,gender,prior history,individual history,admission NIHSS score,admission mRS score,and admission BI index.2.Comparison of neurological function between the two groups2.l In terms of the National Institutes of Health Stroke scale(NIHSS)score,there was no significant difference in the NIHSS score between the two groups on the first day of admission,but the NIHSS scores of the control group and the experimental group were significantly lower than those of the experimental group on the 10 th±2nd day and the 90th±7th day of follow-up.The NIHSS score of the experimental group was significantly lower than that of the control group on the 10th±2 day after treatment.After 90±7 days of treatment,there was significant difference between the experimental group and the control group(P<0.01).2.2In terms of modified Rankin scale(mRs),there was no significant difference i n mRS score between the two groups on the first day after hospitalization.The mR S scores of the control group and the experimental group were significantly lower th an those of the control group and the experimental group on the 10th ±2nd day and the 90th±7th day of follow-up.The mRS score of the experimental group was significantl y lower than that of the control group on the 10th±2 day after treatment.After 90±7 days of treatment,there was significant difference between the experimental group and the control group(P<0.01).2.3In terms of Barthel index(BI)rating scale,there was no significant differenc e in BI index between the two groups on the first day after hospitalization.On the 10 th ±2 day and 90 ±7 day follow-up,the BI index of the control group and the experim ental group increased compared with the first day,and the difference was statis tically significant.It was found that the BI index of the experimental group was hig her than that of the control group on the 10th±2nd day and 90 th ±7th day after treat ment,and there was significant difference in BI index between the two groups.3.Comparison of changes of serum indexes between the two groups,there was no significant difference in serum IL-6,hs-CRP and S100B protein levels between the two groups on the first day after hospitalization.After treatment,the serum IL-6,hs-CRP and S100B protein levels in the two groups were significantly lower than those on the first day.The serum IL-6 level in the experimental group was significantly lower than that in the control group after treatment.The levels of serum hs-crp and S100B protein in the control group were significantly different from those in the control group after treatment.ConclusionsAfter intravenous thrombolysis with alteplase combined with Edaravone dexborneol,the therapeutic effect was satisfactory.Edaravone right camphor can reduce the levels of hsCRP,IL-6 and S100B in serum of patients after thrombolysis,which can effectively reduce the inflammatory reaction and protect the blood-brain barrier.Lowering the NIHSS score,mRS score and BI index of the patients is beneficial to the recovery of neurological function and improve the short-term prognosis.And the safety is good,so it is a new treatment scheme worth popularizing.